Review
Series: Superlative Sequels
Heat Shock Proteins Promote Cancer: It's a Protection Racket

https://doi.org/10.1016/j.tibs.2016.01.003Get rights and content

Trends

Molecular chaperones, such as Hsp27, Hsp70, and Hsp90, have elevated expression in a range of cancers, which indicates a poor prognosis in most cases.

HSP expression is essential to many of the distinctive traits of malignant cells, including uncontrolled growth, reduced tumor suppression, enhanced cell survival, and angiogenic and metastatic properties.

Recent studies show that HSPs support cancer stem cell identity, including the capacity for cell renewal, invasion, and metastasis.

Increased levels of Hsp90 aid the rapid evolution of new treatment-resistant phenotypes by permitting new traits to arise within tumors.

HSPs can interact distinctly with different driver oncogenes, which drives the progression of individual cancers.

Extracellular HSPs are of growing importance in the etiology of cancer and may mediate powerful effects on tumor immunity and metastasis.

Heat shock proteins (HSP) are expressed at high levels in cancer and form a fostering environment that is essential for tumor development. Here, we review the recent data in this area, concentrating mainly on Hsp27, Hsp70, and Hsp90. The overriding role of HSPs in cancer is to stabilize the active functions of overexpressed and mutated cancer genes. Thus, elevated HSPs are required for many of the traits that underlie the morbidity of cancer, including increased growth, survival, and formation of secondary cancers. In addition, HSPs participate in the evolution of cancer treatment resistance. HSPs are also released from cancer cells and influence malignant properties by receptor-mediated signaling. Current data strongly support efforts to target HSPs in cancer treatment.

Section snippets

Introduction to HSPs, Chaperones, and Cancer

HSPs are the effector components of a universal, explosive response to cellular stresses, most notably heat shock itself 1, 2. In fact, HSPs are expressed in such quantities after heat shock that they can be visualized as the dominant bands on 1D SDS PAGE gels after Coomassie blue staining; their abundance astonished some of the early investigators in the field. These proteins are synthesized in response to proteomic damage and can be thought of as components of a protein repair kit (Table 1).

HSPs and the Defining Traits of Cancer Cells

When the US President Richard Nixon signed the National Cancer Act in 1971, few would have predicted the complexities that such a ‘war on cancer’ would turn up. However, studies carried out by the cancer research community over the next 30 or so years, led Douglas Hanahan and Robert Weinberg to compile in 2000 a list of accepted ‘Hallmarks’ essential in tumorigenesis including: (i) unregulated proliferation; (ii) evasion of antigrowth signals; (iii) escape from programmed cell death (PCD); (iv)

HSP90: A Pivotal Factor in Evolution, Tumor Progression, and the Origin of Treatment-Resistant Phenotypes

In 1998, the Lindquist Lab made a groundbreaking discovery: that Hsp90 could have a role in Darwinian evolution in cells and organisms [70] (Box 2). Hsp90 appeared to participate in ‘canalization;’ that is, it smoothed over changes in phenotype despite the accumulation of genetic changes that occur naturally. Selection of new traits could be brought about by heat shock in which Hsp90 is sequestered by denatured proteins, or by Hsp90 inhibitors, when mutant conformations are unmasked by

HSF1 and HSPs in Cancer Stem Cells and Tumor Initiation

It has recently become apparent that tumors are heterogeneous at the cellular level and that only a fraction of the cell population is able to seed a new tumor [76]. The small tumor-initiating subpopulations have phenotypes similar to those of tissue stem cells, and are referred to as cancer stem cells (CSCs) (Box 3). The remainder of the tumor cells (nonstem cells, NSC) although continuing to proliferate, have reduced tumor-initiating capacity and therapy resistance and, thus, are not the

HSPs in Transgenic Tumor Models: In Vivo Veritas?

Within tumors, one or more dominant mutation(s) generally occur and these mutated proteins drive the malignant process [87]. Much may be learned about the roles of HSPs in tumorigenesis by studying transgenic mice that have been engineered to express dominant oncogenes. For instance, Sherman et al. discovered an essential role for Hsp70 in the Her2 mouse model [29]. Mammary tumors arising in such mice are a model for the Her2-positive subtype of human breast cancer [29]. In this case, the

Mechanisms: Do We Understand How HSP Levels Increase in Cancer?

We next ask: is there an overall hypothesis to account for the abundance of HSP expression in cancer cells and do such cells have reduced capacity to fold proteins? These questions were directly addressed in studies by Sherman et al., who monitored several criteria associated with cell stress and found that cancer cells do not seem to be in folding deficit [88]. However, there seems little doubt that cancer cells have an increased folding demand. This is evidenced by studies showing that

Extracellular Chaperones: The Jokers in the Pack

Although their existence was originally treated with some skepticism, the biological significance of extracellular HSPs is now growing rapidly. Extracellular HSPs can be proinflammatory in some contexts or show the opposite nature in others 90, 91. When used as vaccines to chaperone tumor antigens, they can stimulate specific tumor immunity and lead to tumor regression [80]. Thus, the direction of their effects appears to depend on the environment. When cells are exposed to elevated Hsp70

Concluding Remarks

There is overwhelming evidence that molecular chaperones, such as Hsp27, Hsp70, and Hsp90, are expressed at elevated levels in a range of cancers and their elevated expression indicates a poor prognosis in most diseases. HSP expression appears essential in many of the distinctive traits of malignant cells, including uncontrolled growth, reduced tumor suppression, enhanced cell survival, and the acquisition of powerful capacities for angiogenesis and metastasis. It was also recently shown that

Acknowledgments

The authors gratefully acknowledge support provided by NIH research grants, RO-1CA119045 and RO-1CA094397 to S.K.C.

References (103)

  • K.A. Whelan

    The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistance

    J. Biol. Chem.

    (2013)
  • S. Masciari

    Gastric cancer in individuals with Li-Fraumeni syndrome

    Genet. Med.

    (2011)
  • D. Chauhan

    Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance

    Blood

    (2003)
  • C. Paul

    Dynamic processes that reflect anti-apoptotic strategies set up by HspB1 (Hsp27)

    Exp. Cell Res.

    (2010)
  • J.V. Joseph

    Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1alpha-ZEB1 axis

    Cancer Lett.

    (2015)
  • J.R. Prensner

    RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1

    Lancet Oncol.

    (2014)
  • A. Viale et al.

    Sugar? No Thank You, Just a Deep Breath of Oxygen for Cancer Stem Cells

    Cell Metab.

    (2015)
  • X. Peng

    Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes

    J. Biol. Chem.

    (2005)
  • J.A. Ajani

    Cancer stem cells: the promise and the potential

    Semin. Oncol.

    (2015)
  • P.K. Sobhan

    Identification of heat shock protein 90 inhibitors to sensitize drug resistant side population tumor cells using a cell based assay platform

    Cancer Lett.

    (2012)
  • S. Salari

    Extracellular HSP27 acts as a signaling molecule to activate NF-kappaB in macrophages

    Cell Stress Chaperones

    (2013)
  • M.W. Hance

    Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer

    J. Biol. Chem.

    (2012)
  • K.D. Nolan

    Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion

    J. Biol. Chem.

    (2015)
  • J.R. Theriault

    Extracellular HSP70 binding to surface receptors present on antigen presenting cells and endothelial/epithelial cells

    FEBS Lett.

    (2005)
  • J.R. Subjeck et al.

    Coexpression of Thermotolerance and Heat Shock Proteins in Mammalian Cells

    (1982)
  • R. Kityk

    Pathways of allosteric regulation in Hsp70 chaperones

    Nat. Commun.

    (2015)
  • S. Lindquist et al.

    The heat-shock proteins

    Annu. Rev. Genet.

    (1988)
  • S.K. Calderwood

    Molecular cochaperones: tumor growth and cancer treatment

    Scientifica

    (2013)
  • M.H. Manjili

    HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice

    J. Immunol.

    (2003)
  • A.P. Arrigo

    Immense Cellular Implications Associated to Small Heat Shock Protein Expression: Impacts on Human Pathologies

    (2015)
  • N.B. Nillegoda

    Crucial HSP70 co-chaperone complex unlocks metazoan protein disaggregation

    Nature

    (2015)
  • G. Calabria

    Hsp70 protein levels and thermotolerance in Drosophila subobscura: a reassessment of the thermal co-adaptation hypothesis

    J. Evol. Biol.

    (2012)
  • S. Yoshida

    Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis

    Proc. Natl. Acad. Sci. U.S.A.

    (2013)
  • D. Picard

    Reduced levels of hsp90 compromise steroid receptor action in vivo

    Nature

    (1990)
  • M. Akerfelt

    Heat shock factors: integrators of cell stress, development and lifespan

    Nat. Rev. Mol. Cell Biol.

    (2010)
  • D.R. Ciocca

    Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update

    Arch. Toxicol.

    (2013)
  • M.Y. Sherman et al.

    Hsp70 in cancer: back to the future

    Oncogene

    (2015)
  • L. Neckers et al.

    Hsp90 molecular chaperone inhibitors: are we there yet?

    Clin. Cancer Res.

    (2012)
  • C. Campanella

    Heat shock protein 60 levels in tissue and circulating exosomes in human large bowel cancer before and after ablative surgery

    Cancer

    (2015)
  • Z. Wang

    N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence

    Proc. Natl. Acad. Sci. U.S.A.

    (2013)
  • D.J. Vander Griend

    Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation

    Int. J. Biol. Sci.

    (2014)
  • L. Meng

    Heat shock protein Hsp72 plays an essential role in Her2-induced mammary tumorigenesis

    Oncogene

    (2011)
  • M. Momeny

    Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines

    Oncotarget

    (2015)
  • P.J. Gray

    Targeting the oncogene and kinome chaperone CDC37

    Nat. Rev. Cancer

    (2008)
  • M.A. Khaleque

    Induction of heat shock proteins by heregulin beta1 leads to protection from apoptosis and anchorage-independent growth

    Oncogene

    (2005)
  • A. Kamal

    A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

    Nature

    (2003)
  • J. Agorreta

    TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC

    Mol. Cancer Res.

    (2014)
  • J. Gong

    Targeting the hsp70 gene delays mammary tumor initiation and inhibits tumor cell metastasis

    Oncogene

    (2015)
  • O. Pinhasi-Kimhi

    Specific interaction between the p53 cellular tumour antigen and major heat shock proteins

    Nature

    (1986)
  • M. Wiech

    Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2

    PLoS ONE

    (2012)
  • Cited by (300)

    • Decoding the roles of heat shock proteins in liver cancer

      2024, Cytokine and Growth Factor Reviews
    View all citing articles on Scopus
    View full text